• About us
• Contact

Advertisement

Organisation › Details

4SC AG (FSE: VSC)

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: Kinselby – resminostat. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 16 employees as of 30 June 2023 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40). *

 

	Start	1997-01-01 established_pre
	Group	4SC (Group)
	Predecessor	4SC GmbH
	Industry	resminostat (4SC-201, Kinselby)
	Person	Loveridge, Jason (4SC 201609– CEO)
	Person 2	Doppler, Clemens (3i Germany 2007 Director Healthcare Team)
	Region	Martinsried
	Country	Germany
	Street	22 Fraunhoferstr.
	City	82152 Martinsried
	Tel	+49-89-700763-0
		Address record changed: 2022-09-17
Basic data	Employees	B: 11 to 50 (2019-12-31)
	Currency	EUR
	Annual sales	2,196,000 (revenue, consolidated (2019) 2019-12-31)
	Profit	-13,962,000 (2019-12-31)
	Cash	31,727,000 (2019-12-31)
		* Document for »About Section«: 4SC AG. (9/27/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL from the US FDA". Planegg-Martinsried.
		Record changed: 2023-10-31

Advertisement

More documents for 4SC (Group)

• [1] 4SC AG. (10/18/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL in the European Union". Planegg-Martinsried....
• [2] 4SC AG. (9/27/23). "Press Release: 4SC Receives Orphan Drug Designation (ODD) for Resminostat (Kinselby) in CTCL from the US FDA". Planegg-Martinsried....
• [3] Immunic, Inc.. (3/31/21). "Press Release: Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838". New York, NY & Planegg-Martinsried....
• [4] 4SC AG. (11/25/20). "Press Release: 4SC AG Resolves to Issue New Shares with Expected Proceeds of approx. EUR 7.5 Million (ad hoc) [not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried....
• [5] 4SC AG. (9/11/20). "Press Release: 4SC and Maruho Discontinue Collaboration for Development of 4SC’s Kv1.3 Inhibitors". Planegg-Martinsried....
• [6] 4SC AG. (11/12/19). "Press Release: 4SC AG Secures circa EUR 22.4 Million from a Capital Increase [Not for release in US, Australia, Canada, et al.]". Planegg-Martinsried....
• [7] 4SC AG. (10/7/19). "Press Release: 4SC AG Resolves to Issue New Shares, Santo and ATS Undertake to Subscribe / Buy the New Shares [Not for US, AU, CA, et al.]". Planegg-Martinsried....
• [8] 4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried....
• [9] 4SC AG. (3/20/19). "Press Release: 4SC AG Provides Results for Financial Year 2018 and Outlook". Planegg-Martinsried....
• [10] 4SC AG. (3/7/19). "Press Release: 9 Upcoming Conferences and Roadshows". Planegg-Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.